backJoin our experienced panelists for a review of key takeaways from the FDA’s 2024 drug and device advertising and promotion enforcement letters.
Other topics include:
- FDA’s new “Addressing Misinformation” guidance;
- FDA’s “CCN” final rule for presentation of the major statement in DTC prescription drug ads and related DTC TV trends;
- FTC updates;
- OPDP research initiatives; and
- predictions for what may be expected in 2025.